ABL1 and gastrointestinal stromal tumor: For example, sunitinib and regorafenib, the FDA-approved second- and third-line treatments for imatinib-resistant GIST do not significantly inhibit ABL1 compared to imatinib as shown in an in vitro kinase assay (Figure 5).